Loading...
Market
By how much will Exscientia's GenAI platform reduce drug discovery time by the end of 2024?
2
Resolution / Starting Odds
Less than 1 year • 25%
1-2 years • 25%
2-3 years • 25%
More than 3 years • 25%
Official reports or studies published by Exscientia or third-party research
Story
Exscientia Launches AWS-Powered GenAI Platform for Drug Discovery
Jul 10, 2024, 11:13 AM
Exscientia has launched a state-of-the-art GenAI platform to advance drug discovery, built using AWS technology. The platform integrates generative AI drug design and robotic lab automation to accelerate the delivery of high-quality drugs at faster speeds and lower costs. This development signifies a significant shift in the drug discovery landscape, leveraging massive proprietary datasets and AI to produce intelligence that leads to drug production. Jensen Huang highlighted the scale of data and compute reaching an inflection point in this field.
View original story
Similar markets
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
